Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVSNASDAQ:ELUTNASDAQ:GOSSNASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$3.93-0.3%$3.66$1.75▼$10.00$268.59M0.57769,103 shs644,192 shsELUTElutia$1.79+1.1%$1.96$1.61▼$5.24$72.78M0.8647,268 shs6,936 shsGOSSGossamer Bio$1.29+4.0%$1.08$0.55▼$1.55$281.86M1.851.48 million shs691,491 shsPROKProKidney$0.70-19.0%$0.81$0.46▼$2.75$251.10M1.35631,137 shs1.28 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals-0.25%-12.67%+8.56%-6.65%+110.16%ELUTElutia+1.13%-10.95%-1.10%-44.75%-45.26%GOSSGossamer Bio+4.03%0.00%+18.35%-4.44%+137.83%PROKProKidney-18.84%-25.52%-13.87%-26.11%-74.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRVSCorvus Pharmaceuticals2.5755 of 5 stars3.52.00.00.02.12.50.6ELUTElutia3.6981 of 5 stars3.55.00.00.02.83.30.6GOSSGossamer Bio3.6886 of 5 stars3.51.00.04.72.21.70.0PROKProKidney1.7393 of 5 stars3.20.00.00.00.64.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVSCorvus Pharmaceuticals 3.00Buy$15.00281.68% UpsideELUTElutia 3.00Buy$8.00346.93% UpsideGOSSGossamer Bio 3.00Buy$7.75500.78% UpsidePROKProKidney 2.33Hold$4.50546.27% UpsideCurrent Analyst Ratings BreakdownLatest ELUT, GOSS, CRVS, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025CRVSCorvus PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$12.00 ➝ $11.005/16/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/16/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.005/9/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.005/9/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.004/17/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.003/26/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$14.00 ➝ $15.003/26/2025CRVSCorvus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/AELUTElutia$24.38M3.02N/AN/A($1.31) per share-1.37GOSSGossamer Bio$114.70M2.56N/AN/A$0.13 per share9.92PROKProKidney$80K2,547.59N/AN/A($3.41) per share-0.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVSCorvus Pharmaceuticals-$62.29M-$0.98N/AN/AN/AN/A-24.04%-13.90%8/5/2025 (Estimated)ELUTElutia-$53.95M-$1.93N/AN/AN/A-168.23%N/A-96.70%7/28/2025 (Estimated)GOSSGossamer Bio-$56.53M-$0.23N/AN/AN/A-41.12%-128.98%-15.52%8/11/2025 (Estimated)PROKProKidney-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)Latest ELUT, GOSS, CRVS, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GOSSGossamer Bio-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/8/2025Q1 2025CRVSCorvus Pharmaceuticals-$0.13-$0.13N/A-$0.13N/AN/A5/8/2025Q1 2025ELUTElutia-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 million3/25/2025Q4 2024CRVSCorvus Pharmaceuticals-$0.12-$0.18-$0.06-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVSCorvus PharmaceuticalsN/A4.904.90ELUTElutiaN/A0.810.70GOSSGossamer Bio6.705.715.71PROKProKidneyN/A10.9610.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVSCorvus Pharmaceuticals46.64%ELUTElutia74.03%GOSSGossamer Bio81.23%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipCRVSCorvus Pharmaceuticals28.50%ELUTElutia27.60%GOSSGossamer Bio6.70%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVSCorvus Pharmaceuticals3068.17 million48.74 millionOptionableELUTElutia18041.12 million29.77 millionNot OptionableGOSSGossamer Bio180227.30 million212.07 millionOptionablePROKProKidney3292.70 million171.26 millionOptionableELUT, GOSS, CRVS, and PROK HeadlinesRecent News About These CompaniesHennion & Walsh Asset Management Inc. Has $740,000 Stake in ProKidney Corp. (NASDAQ:PROK)June 8, 2025 | marketbeat.comProKidney quarterly loss grows as it nears two key milestonesMay 15, 2025 | journalnow.comProKidney Reports First Quarter 2025 Financial Results and Business HighlightsMay 12, 2025 | globenewswire.comAnother Big Office Landlord Tests Sales ClimateMay 12, 2025 | bankerandtradesman.comPROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comWhy ProKidney Corp.’s (PROK) Stock Is Down 6.09%April 28, 2025 | aaii.comInsider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Purchases 387,393 Shares of StockApril 25, 2025 | insidertrades.comWhy ProKidney Corp.’s (PROK) Stock Is Down 7.90%April 17, 2025 | aaii.comProKidney Corp. (NASDAQ:PROK) Insider Buys $195,716.65 in StockApril 17, 2025 | insidertrades.comGreensboro’s Once Great Win Is Now A ProKidney FailureApril 16, 2025 | rhinotimes.comControl Empresarial De Capital Buys 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) StockApril 15, 2025 | insidertrades.comWhy ProKidney Corp.’s (PROK) Stock Is Down 9.90%April 10, 2025 | aaii.comWhy ProKidney Corp.’s (PROK) Stock Is Down 14.87%April 8, 2025 | aaii.comProKidney Corp.March 30, 2025 | wsj.comHere's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn SituationMarch 27, 2025 | finance.yahoo.comDown -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)March 21, 2025 | zacks.comProKidney reports larger loss in 2024 as production resumesMarch 18, 2025 | journalnow.comProKidney reports FY24 EPS (62c), consensus (59c)March 17, 2025 | markets.businessinsider.comProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney DiseaseMarch 17, 2025 | quiverquant.comProKidney Reports Full Year 2024 Financial Results and Business HighlightsMarch 17, 2025 | globenewswire.comWhy ProKidney Corp.’s (PROK) Stock Is Down 10.96%February 26, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELUT, GOSS, CRVS, and PROK Company DescriptionsCorvus Pharmaceuticals NASDAQ:CRVS$3.93 -0.01 (-0.25%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$4.04 +0.12 (+2.93%) As of 06/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Elutia NASDAQ:ELUT$1.79 +0.02 (+1.13%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.80 +0.01 (+0.56%) As of 06/18/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Gossamer Bio NASDAQ:GOSS$1.29 +0.05 (+4.03%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.30 +0.00 (+0.39%) As of 06/18/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.ProKidney NASDAQ:PROK$0.70 -0.16 (-19.03%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.75 +0.05 (+7.28%) As of 06/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
